Zde se nacházíte:
Informace o publikaci
The cost study of treating mCRC with bevacizumab plus chemotherapy in the real clinical practice in the Czech Republic
Autoři | |
---|---|
Rok publikování | 2012 |
Druh | Konferenční abstrakty |
Citace | |
Popis | Bevacizumab, a humanized monoclonal IgG antibody against the vascular endothelial growth factor (VEGF), is reimbursed in the Czech Republic in combination with chemotherapy for the first-line treatment of patients with metastatic colorectal cancer (mCRC). However, its high cost is a potentially limiting factor. |